Supplementary Figure 5: Dependence of C1q expression in AMs on PPAR-δ

(A) WT AM were pre-treated for 24h with the indicated doses of the PPAR-δ activator GW0742 in combination with the PPAR-δ inhibitor GSK3787 along with a DMSO control after which RT-PCR of *C1qb* and *C1qc* was performed. **(B)** WT and *Trem-2[-/-]* AM were treated with DMSO or the PPAR-δ inhibitor GSK3787 after which RT-PCR of *C1qb* and *C1qc* was performed. Data are presented as mean ± SEM and compared versus WT with * $p < 0.05$, ** $p < 0.005$.